Caplin Point Laboratories Share Price Targets
|
Caplin Point Laboratories Limited |
|||
|
Price: ₹2,364.60 (-1.79%) | ||
| 52 Week Low: ₹1,500.30 52 Week High: ₹2,447.30 |
|||
| Market Capital: 13,461.53 Crore (Mid-cap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Caplin Point Laboratories Stock Comparison: Caplin Point Laboratories vs Suven Pharmaceuticals | Caplin Point Laboratories vs Granules India | Caplin Point Laboratories vs AstraZeneca Pharma | Caplin Point Laboratories vs Marksans Pharma | Caplin Point Laboratories vs Glenmark Life Sciences | Caplin Point Laboratories vs Poly Medicure |
|||
Share Price HistoryCAPLIPOINT FinancialsTomorrow TargetYearly TargetsDividend HistoryNo BonusSplit History
Show Table of Contents
Table of Contents
Caplin Point Laboratories Recent Performance
Over the past 756 trading days, the value of Caplin Point Laboratories's stock has gained ₹1,621.20 (+218.08%). On 30 May 2023, one share was worth ₹743.40 and by 15 Jun 2026, the value jumped to ₹2364.60. During this period it created a highest high of ₹2641.00 and lowest low of ₹736.05.
Caplin Point Laboratories Share Price Target - Tomorrow
| Level | Value | Analysis |
|---|---|---|
| Tomorrow Target 3 | 2535.1 (+7.21%) | Volatility: ATR T2 |
| Tomorrow Target 2 | 2466.9 (+4.32%) | Volatility: ATR T1 |
| Tomorrow Target 1 | 2380.43 (+0.66%) | Volatility: BB Upper |
| Current Price | 2364.60 | Caplin Point Laboratories's share price as of 15 Jun 2026 |
| Stop Loss 1 | 2273.41 (-3.86%) | 23.60% Fib Retrace |
| Stop Loss 2 | 2262.3 (-4.33%) | Volatility: ATR S1 |
| Stop Loss 3 | 2242.71 (-5.16%) | Trend: EMA9 |
Summary
15 Jun 2026: Caplin Point Laboratories finished the day at ₹2364.60, losing ₹-43.20 (-1.79%) in 1 day.
Our analysis for tomorrow predicts a potential movement of -5.15% to 7.21% with:
- Target prices: ₹2380.43 to ₹2535.1
- Support levels: ₹2273.41 to ₹2242.71
- Recent high: ₹2447.30
- Recent low: ₹2349.60
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Caplin Point Laboratories Share Price Target - Next Week
| Level | Value | Analysis |
|---|---|---|
| Next Week Target 3 | 2535.1 (+7.21%) | Volatility: ATR T2 |
| Next Week Target 2 | 2466.9 (+4.32%) | Volatility: ATR T1 |
| Next Week Target 1 | 2380.43 (+0.66%) | Volatility: BB Upper |
| Current Price | 2364.60 | Caplin Point Laboratories's share price as of 15 Jun 2026 |
| Stop Loss 1 | 2262.3 (-4.33%) | Volatility: ATR S1 |
| Stop Loss 2 | 2242.71 (-5.16%) | Trend: EMA9 |
| Stop Loss 3 | 2223.8 (-5.96%) | 23.60% Fib Retrace |
Weekly Target Summary
For next week, our analysis suggests a potential movement range of -5.95% to 7.21% with:
- Upper targets: ₹2380.43 to ₹2535.1
- Support levels: ₹2262.3 to ₹2223.8
Caplin Point Laboratories Share Price Target - Next Month
| Level | Value | Analysis |
|---|---|---|
| Next Month Target 3 | 2643.23 (+11.78%) | 123.60% Weekly Fib Ext |
| Next Month Target 2 | 2537.44 (+7.3%) | Volatility: ATR T1 |
| Next Month Target 1 | 2380.43 (+0.66%) | Volatility: BB Upper |
| Current Price | 2364.60 | Caplin Point Laboratories's share price as of 15 Jun 2026 |
| Stop Loss 1 | 2242.71 (-5.16%) | Trend: EMA9 |
| Stop Loss 2 | 2191.76 (-7.31%) | Volatility: ATR S1 |
| Stop Loss 3 | 2076.54 (-12.19%) | Volatility: ATR S2 |
Monthly Target Summary
Looking ahead to next month, technical analysis indicates:
- Potential price movement: -12.18% to 11.78% with:
- Target range: ₹2380.43 to ₹2643.23
- Support levels: ₹2242.71 to ₹2076.54
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
